(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/156979 A1

(51) International Patent Classification:
A61K 9/20 (2006.01)

(21) International Application Number:
PCT/IB2023/051532

(22) International Filing Date:
20 February 2023 (20.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202211009181 21 February 2022 (21.02.2022) IN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).


(72) Inventors: **GURURAJAN, Bindhumadhavan**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **REYNAUD, Emeric**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **ROGUE, Vincent**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **LOWALEKAR, Rohit**; c/o Novartis Healthcare Private Limited, Plot no. 11, Survey no. 101, Lalgadi Malakpet, Turkapally, Shamirpet, Rangareddy distr. Genome Valley, Hyderabad 500078 (IN). **PAWAR, Yogesh**; c/o Novartis Healthcare Private Limited, Plot no. 11, Survey no. 101, Lalgadi Malakpet, Turkapally, Shamirpet, Rangareddy distr. Genome Valley, Hyderabad 500078 (IN). **SAWAI, Tushar**; c/o Novartis Healthcare Private Limited, Plot no. 11, Survey no. 101, Lalgadi Malakpet, Turkapally, Shamirpet, Rangareddy distr. Genome Valley, Hyderabad 500078 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL FORMULATION

FIG. 1



(57) Abstract: The invention relates to a pharmaceutical formulation comprising the Active Pharmaceutical Ingredient (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-amine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, where, in particular, the pharmaceutical formulation is made by a process comprising wet granulation, direct compression or especially roller compaction, and related invention aspects disclosed herein.

WO 2023/156979 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*